Effectiveness of Prenatal Vitamin D Deficiency Screening and Treatment Program: A Stratified Randomized Field Trial

• Published in: The journal of clinical endocrinology and metabolism Vol. 103; no. 8; pp. 2936 - 2948
• Main Authors: Rostami, Maryam, Tehrani, Fahimeh Ramezani, Simbar, Masoumeh, Bidhendi Yarandi, Razieh, Minooee, Sonia, Hollis, Bruce W, Hosseinpanah, Farhad
• Format: Journal Article
• Language: English
• Published: Washington, DC Endocrine Society 01.08.2018; Copyright Oxford University Press; Oxford University Press
• Subjects: 25-Hydroxyvitamin D; Complications; Diabetes mellitus; Pre-eclampsia; Pregnancy; Pregnancy complications; Randomization; Supplements; Vitamin D; Vitamin D3; Vitamin deficiency; Womens health
• ISSN: 0021-972X; 1945-7197
• DOI: 10.1210/jc.2018-00109

Abstract Context Despite evidence on the association between hypovitaminosis D and adverse pregnancy outcomes and the positive impact of vitamin D supplementation, no evidence exists supporting a universal screening program in pregnancy as part of routine prenatal care. Objective We sought to determine the effectiveness of a prenatal screening program on optimizing 25-hydroxyvitamin D [25(OH)D] levels and preventing pregnancy complications. Also, to identify a safe regimen, we compared several regimens in a subgroup of vitamin D–deficient pregnant women. Design Two cities of Masjed-Soleyman and Shushtar from Khuzestan province, Iran, were selected as the screening and nonscreening arms, respectively. Within the screening arm, a randomized controlled trial was conducted on 800 pregnant women. Setting Health centers of Masjed-Soleyman and Shushtar cities. Patients or Participants Pregnant women aged 18 to 40 years. Intervention Women with moderate [25(OH)D, 10 to 20 ng/mL] and severe [25(OH)D, <10 ng/mL] deficiency were randomly divided into four subgroups and received vitamin D3 (D3) until delivery. Main Outcome Measure Maternal concentration of 25(OH)D at delivery and rate of pregnancy complications Results After supplementation, only 2% of the women in the nonscreening site met the sufficiency level (>20 ng/mL) vs 53% of the women in the screening site. Adverse pregnancy outcomes, including preeclampsia, gestational diabetes mellitus, and preterm delivery, were decreased by 60%, 50%, and 40%, respectively, in the screening site. A D3 injection in addition to monthly 50,000 IU maintenance therapy contributed the most to achievement of sufficient levels at delivery. Conclusions A prenatal vitamin D screening and treatment program is an effective approach in detecting deficient women, improving 25(OH)D levels, and decreasing pregnancy adverse outcomes. Vitamin D screening policy is beneficial in improving maternal outcomes. A high-dose vitamin D3 administration plus monthly maintenance regimen was efficient in women with baseline levels <20 ng/mL.